CMBs carrying PTX and CRISPR/Cas9 targeting <em>C‑erbB‑2</em> plasmids interfere with endometrial cancer cells

Peng,Siyuan; Cai,Junhong; Bao,Shan

doi:10.3892/mmr.2021.12470

CMBs carrying PTX and CRISPR/Cas9 targeting C‑erbB‑2 plasmids interfere with endometrial cancer cells

Authors:
- Siyuan Peng
- Junhong Cai
- Shan Bao
View Affiliations

Affiliations: Department of Gynaecology and Obstetrics, Hainan Hospital Affiliated to University of South China, Haikou, Hainan 570311, P.R. China, Key Laboratory of Cell and Molecular Genetic Translational Medicine in Hainan Province, Hainan General Hospital, Haikou, Hainan 570311, P.R. China, Department of Gynaecology and Obstetrics, Hainan General Hospital/Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570311, P.R. China
Published online on: September 28, 2021 https://doi.org/10.3892/mmr.2021.12470
Article Number: 830
Copyright: © Peng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Development of combination therapy to decrease side effects of chemotherapeutic drugs and increase their utilization rate in combination with gene editing is a key research topic in tumor treatment. The present study aimed to investigate the effect of cationic microbubbles (CMBs) carrying paclitaxel (PTX) and C‑erbB‑2 knockout plasmid on the endometrial cancer cell line HEC‑1A and to determine how C‑erbB‑2 regulates the function of endometrial cancer cells. Cells were treated with CMB, PTX, PTX‑CMBs, cationic plasmid‑carrying or cationic PTX‑carrying plasmid groups. After verifying the most effective combination of PTX‑CMBs and plasmids, HEC‑1A cells were transfected. Reverse transcription‑quantitative (RT‑q)PCR and western blotting were used to measure C‑erbB‑2 and protein expression. After verifying C‑erbB‑2 knockout, invasion, healing, clone formation and proliferation of HEC‑1A cells were assessed. Simultaneously, expression levels of the genes for P21, P27, mammalian target of rapamycin (mTOR), and Bcl‑2 associated death promoter (Bad) were measured by RT‑qPCR. Compared with the PTX group, CMBs significantly enhanced the absorption efficiency of PTX by HEC‑1A cells. C‑erbB‑2 knockout had an inhibitory effect on the proliferation, migration and invasion of HEC‑1A cells; cell proliferation and invasion of the group carrying PTX and plasmids simultaneously were significantly weakened. The C‑erbB‑2‑knockout group exhibited increased expression of P21 and P27. Simultaneously loading PTX and plasmid may be novel combination therapy with great potential. C‑erbB‑2 may regulate the proliferation of HEC‑1A cells by downregulating expression of P21 and P27.

View Figures

View References

1	Lu KH and Broaddus RR: Endometrial Cancer. N Engl J Med. 383:2053–2064. 2020. View Article : Google Scholar : PubMed/NCBI
2	Njoku K, Abiola J, Russell J and Crosbie EJ: Endometrial cancer prevention in high-risk women. Best Pract Res Clin Obstet Gynaecol. 65:66–78. 2020. View Article : Google Scholar : PubMed/NCBI
3	Aoki Y, Kanao H, Wang X, Yunokawa M, Omatsu K, Fusegi A and Takeshima N: Adjuvant treatment of endometrial cancer today. Jpn J Clin Oncol. 50:753–765. 2020. View Article : Google Scholar : PubMed/NCBI
4	Habibi Jouybari M, Hosseini S, Mahboobnia K, Boloursaz LA, Moradi M and Irani M: Simultaneous controlled release of 5-FU, DOX and PTX from chitosan/PLA/5-FU/g-C3N4-DOX/g-C3N4-PTX triaxial nanofibers for breast cancer treatment in vitro. Colloids Surf B Biointerfaces. 179:495–504. 2019. View Article : Google Scholar : PubMed/NCBI
5	Zhou X, Cao C, Li N and Yuan S: SYL3C aptamer-anchored microemulsion co-loading β-elemene and PTX enhances the treatment of colorectal cancer. Drug Deliv. 26:886–897. 2019. View Article : Google Scholar : PubMed/NCBI
6	Ebeid K, Meng X, Thiel KW, Do AV, Geary SM, Morris AS, Pham EL, Wongrakpanich A, Chhonker YS, Murry DJ, et al: Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat Nanotechnol. 13:72–81. 2018. View Article : Google Scholar : PubMed/NCBI
7	Dinkic C, Kruse A, Zygmunt M, Schuetz F, Brucker J, Rom J, Sohn C and Fluhr H: Influence of Paclitaxel and Heparin on Vitality, Proliferation and Cytokine Production of Endometrial Cancer Cells. Geburtshilfe Frauenheilkd. 77:1104–1110. 2017. View Article : Google Scholar : PubMed/NCBI
8	Zhang Q, Liu F, Wang B, Li Z, Zhou D, Yang Q, Dong J and Li J: HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma: A systematic review and meta-analysis of 16 studies. Medicine (Baltimore). 95:e36612016. View Article : Google Scholar : PubMed/NCBI
9	Press MF, Cordon-Cardo C and Slamon DJ: Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 5:953–962. 1990.PubMed/NCBI
10	Mori S, Akiyama T, Yamada Y, Morishita Y, Sugawara I, Toyoshima K and Yamamoto T: C-erbB-2 gene product, a membrane protein commonly expressed on human fetal epithelial cells. Lab Invest. 61:93–97. 1989.PubMed/NCBI
11	Hua S, Chuanbo F, Zhonglin W, Shuangjiu Z and Xinwen Z: The expression and prognostic significance of Topo-II and c-erbB-2 in breast cancer. Minerva Med. Jul 17–2020.(Epub ahead of print). doi: 10.23736/S0026-4806.20.06637-9. PubMed/NCBI
12	Wang K, Liu J, Duan Y, Wu J, Dongye S, Wang Y, Liu Z and Han G: C-erbB-2 expression is related with pathological progression of gastric cancer: Results of a non-radioactive in situ hybridization. Int J Clin Exp Pathol. 10:9649–9653. 2017.PubMed/NCBI
13	Canoz O, Ozkan M, Arsav V, Er O, Coskun HS, Soyuer S and Altinbas M: The role of c-erbB-2 expression on the survival of patients with small-cell lung cancer. Lung. 184:267–272. 2006. View Article : Google Scholar : PubMed/NCBI
14	Xiao W, Dong X, Zhao H, Han S, Nie R, Zhang X and An R: Expression of MIF and c-erbB-2 in endometrial cancer. Mol Med Rep. 13:3828–3834. 2016. View Article : Google Scholar : PubMed/NCBI
15	Zhou Q, Hou CN, Yang HJ, He Z and Zuo MZ: Distinct expression and prognostic value of members of the epidermal growth factor receptor family in ovarian cancer. Cancer Manag Res. 10:6937–6948. 2018. View Article : Google Scholar : PubMed/NCBI
16	Li BT, Ross DS, Aisner DL, Chaft JE, Hsu M, Kako SL, Kris MG, Varella-Garcia M and Arcila ME: HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. J Thorac Oncol. 11:414–419. 2016. View Article : Google Scholar : PubMed/NCBI
17	Erickson BK, Zeybek B, Santin AD and Fader AN: Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. Curr Opin Obstet Gynecol. 32:57–64. 2020. View Article : Google Scholar : PubMed/NCBI
18	Cho S, Shin J and Cho BK: Applications of CRISPR/Cas System to Bacterial Metabolic Engineering. Int J Mol Sci. 19:10892018. View Article : Google Scholar : PubMed/NCBI
19	Ishino Y, Shinagawa H, Makino K, Amemura M and Nakata A: Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. 169:5429–5433. 1987. View Article : Google Scholar : PubMed/NCBI
20	Hryhorowicz M, Lipiński D, Zeyland J and Słomski R: CRISPR/Cas9 Immune System as a Tool for Genome Engineering. Arch Immunol Ther Exp (Warsz). 65:233–240. 2017. View Article : Google Scholar : PubMed/NCBI
21	Zhan T, Rindtorff N, Betge J, Ebert MP and Boutros M: CRISPR/Cas9 for cancer research and therapy. Semin Cancer Biol. 55:106–119. 2019. View Article : Google Scholar : PubMed/NCBI
22	Gupta D, Bhattacharjee O, Mandal D, Sen MK, Dey D, Dasgupta A, Kazi TA, Gupta R, Sinharoy S, Acharya K, et al: CRISPR-Cas9 system: A new-fangled dawn in gene editing. Life Sci. 232:1166362019. View Article : Google Scholar : PubMed/NCBI
23	Liu C, Zhang L, Liu H and Cheng K: Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release. 266:17–26. 2017. View Article : Google Scholar : PubMed/NCBI
24	Yang F, Li Y, Liufu C, Wang Y and Chen Z: Preparation of Cationic Lipid-coated Ultrasound Contrast Agents and Noninvasive Gene Transfection Via Ultrasound-targeted Microbubble Destruction. Curr Pharm Des. 24:3587–3595. 2018. View Article : Google Scholar : PubMed/NCBI
25	Delalande A, Bastié C, Pigeon L, Manta S, Lebertre M, Mignet N, Midoux P and Pichon C: Cationic gas-filled microbubbles for ultrasound-based nucleic acids delivery. Biosci Rep. 37:BSR201606192017. View Article : Google Scholar : PubMed/NCBI
26	Zhou Q, Deng Q, Hu B, Wang YJ, Chen JL, Cui JJ, Cao S and Song HN: Ultrasound combined with targeted cationic microbubble-mediated angiogenesis gene transfection improves ischemic heart function. Exp Ther Med. 13:2293–2303. 2017. View Article : Google Scholar : PubMed/NCBI
27	Manta S, Renault G, Delalande A, Couture O, Lagoutte I, Seguin J, Lager F, Houzé P, Midoux P, Bessodes M, et al: Cationic microbubbles and antibiotic-free miniplasmid for sustained ultrasound-mediated transgene expression in liver. J Control Release. 262:170–181. 2017. View Article : Google Scholar : PubMed/NCBI
28	Arocho A, Chen B, Ladanyi M and Pan Q: Validation of the 2-DeltaDeltaCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts. Diagn Mol Pathol. 15:56–61. 2006. View Article : Google Scholar : PubMed/NCBI
29	Xu X, Wan T, Xin H, Li D, Pan H, Wu J and Ping Y: Delivery of CRISPR/Cas9 for therapeutic genome editing. J Gene Med. 21:e31072019. View Article : Google Scholar : PubMed/NCBI
30	Lino CA, Harper JC, Carney JP and Timlin JA: Delivering CRISPR: A review of the challenges and approaches. Drug Deliv. 25:1234–1257. 2018. View Article : Google Scholar : PubMed/NCBI
31	Chen M, Mao A, Xu M, Weng Q, Mao J and Ji J: CRISPR-Cas9 for cancer therapy: Opportunities and challenges. Cancer Lett. 447:48–55. 2019. View Article : Google Scholar : PubMed/NCBI
32	Yip BH: Recent Advances in CRISPR/Cas9 Delivery Strategies. Biomolecules. 10:8392020. View Article : Google Scholar : PubMed/NCBI
33	Wang Y, Li X, Liu L, Liu B, Wang F and Chen C: Tissue Targeting and Ultrasound-Targeted Microbubble Destruction Delivery of Plasmid DNA and Transfection In Vitro. Cell Mol Bioeng. 13:99–112. 2019. View Article : Google Scholar : PubMed/NCBI
34	Kooiman K, Roovers S, Langeveld SAG, Kleven RT, Dewitte H, O'Reilly MA, Escoffre JM, Bouakaz A, Verweij MD, Hynynen K, et al: Ultrasound-Responsive Cavitation Nuclei for Therapy and Drug Delivery. Ultrasound Med Biol. 46:1296–1325. 2020. View Article : Google Scholar : PubMed/NCBI
35	Zhu X, Guo J, He C, Geng H, Yu G, Li J, Zheng H, Ji X and Yan F: Ultrasound triggered image-guided drug delivery to inhibit vascular reconstruction via paclitaxel-loaded microbubbles. Sci Rep. 6:216832016. View Article : Google Scholar : PubMed/NCBI
36	Zhang D, Yang L, Tian H, Fu B, Chen W, Liu K, Jia Z, Jiang S, Han X and Sun L: [Enhancement of gene transfection efficiency and therapeutic effect of ultrasound-targeted microbubble destruction in vivo with cationic microbubble]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 32:228–236. 2018.(In Chinese). PubMed/NCBI
37	Du M, Chen Z, Chen Y and Li Y: Ultrasound-Targeted Delivery Technology: A Novel Strategy for Tumor- Targeted Therapy. Curr Drug Targets. 20:220–231. 2019. View Article : Google Scholar : PubMed/NCBI
38	de Leon A, Perera R, Nittayacharn P, Cooley M, Jung O and Exner AA: Ultrasound Contrast Agents and Delivery Systems in Cancer Detection and Therapy. Adv Cancer Res. 139:57–84. 2018. View Article : Google Scholar : PubMed/NCBI
39	Endo-Takahashi Y and Negishi Y: Microbubbles and Nanobubbles with Ultrasound for Systemic Gene Delivery. Pharmaceutics. 12:9642020. View Article : Google Scholar : PubMed/NCBI
40	Qian L, Thapa B, Hong J, Zhang Y, Zhu M, Chu M, Yao J and Xu D: The present and future role of ultrasound targeted microbubble destruction in preclinical studies of cardiac gene therapy. J Thorac Dis. 10:1099–1111. 2018. View Article : Google Scholar : PubMed/NCBI
41	Szablowski JO, Bar-Zion A and Shapiro MG: Achieving Spatial and Molecular Specificity with Ultrasound-Targeted Biomolecular Nanotherapeutics. Acc Chem Res. 52:2427–2434. 2019. View Article : Google Scholar : PubMed/NCBI
42	Zhou LQ, Li P, Cui XW and Dietrich CF: Ultrasound nanotheranostics in fighting cancer: Advances and prospects. Cancer Lett. 470:204–219. 2020. View Article : Google Scholar : PubMed/NCBI
43	Wu J, Chen J, Feng Y, Zhang S, Lin L, Guo Z, Sun P, Xu C, Tian H and Chen X: An immune cocktail therapy to realize multiple boosting of the cancer-immunity cycle by combination of drug/gene delivery nanoparticles. Sci Adv. 6:eabc78282020. View Article : Google Scholar : PubMed/NCBI
44	Liu P, Liu X, Cheng Y, Zhong S, Shi X, Wang S, Liu M, Ding J and Zhou W: Core-Shell Nanosystems for Self-Activated Drug-Gene Combinations against Triple-Negative Breast Cancer. ACS Appl Mater Interfaces. 12:53654–53664. 2020. View Article : Google Scholar : PubMed/NCBI
45	Han H, Kim D, Jang Y, Seo M, Kim K, Lee JB and Kim H: Focused ultrasound-triggered chemo-gene therapy with multifunctional nanocomplex for enhancing therapeutic efficacy. J Control Release. 322:346–356. 2020. View Article : Google Scholar : PubMed/NCBI
46	Zhou X, Yang Y, Ma P, Wang N, Yang D, Tu Q, Sun B, Xiang T, Zhao X, Hou Z, et al: TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway. J Neurooncol. 145:211–222. 2019. View Article : Google Scholar : PubMed/NCBI
47	Shamloo B and Usluer S: p21 in Cancer Research. Cancers (Basel). 11:11782019. View Article : Google Scholar : PubMed/NCBI
48	Rodriguez-Cupello C, Dam M, Serini L, Wang S, Lindgren D, Englund E, Kjellman P, Axelson H, García-Mariscal A and Madsen CD: The STRIPAK Complex Regulates Response to Chemotherapy Through p21 and p27. Front Cell Dev Biol. 8:1462020. View Article : Google Scholar : PubMed/NCBI
49	Huang Y, Wang W, Chen Y, Huang Y, Zhang J, He S, Tan Y, Qiang F, Li A, Røe OD, et al: The opposite prognostic significance of nuclear and cytoplasmic p21 expression in resectable gastric cancer patients. J Gastroenterol. 49:1441–1452. 2014. View Article : Google Scholar : PubMed/NCBI
50	Razavipour SF, Harikumar KB and Slingerland JM: p27 as a Transcriptional Regulator: New Roles in Development and Cancer. Cancer Res. 80:3451–3458. 2020. View Article : Google Scholar : PubMed/NCBI
51	Lu P, Redd Bowman KE, Brown SM, Joklik-Mcleod M, Vander Mause ER, Nguyen HTN and Lim CS: p53-Bad: A Novel Tumor Suppressor/Proapoptotic Factor Hybrid Directed to the Mitochondria for Ovarian Cancer Gene Therapy. Mol Pharm. 16:3386–3398. 2019. View Article : Google Scholar : PubMed/NCBI
52	Murugan AK: mTOR: Role in cancer, metastasis and drug resistance. Semin Cancer Biol. 59:92–111. 2019. View Article : Google Scholar : PubMed/NCBI
53	Hua H, Kong Q, Zhang H, Wang J, Luo T and Jiang Y: Targeting mTOR for cancer therapy. J Hematol Oncol. 12:712019. View Article : Google Scholar : PubMed/NCBI
54	Magaway C, Kim E and Jacinto E: Targeting mTOR and Metabolism in Cancer: Lessons and Innovations. Cells. 8:15842019. View Article : Google Scholar : PubMed/NCBI